MedTrace Logo

Low-dose IL-2( Interleukin-2) Treatment in SLE

NCT02084238 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-04-03

Study results available
· View outcomes & findings →

Summary

This clinical study will test the efficacy and safety of low dose IL-2 treatment in Systemic lupus erythematosus.

Conditions

Interventions

DRUG

Interleukin-2

Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.

Sponsors & Collaborators

  • Monash University

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Zhanguo Li, MD and PhD · Peking University Institute of Rheumatology and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2014-11-30
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084238 on ClinicalTrials.gov